Braeburn
Braeburn50
About
What does Braeburn do?
Braeburn Pharmaceuticals is focused on developing long-acting implantable and injectable therapies for opioid addiction and chronic pain. Their lead product, Probufine (buprenorphine implant), is FDA-approved for opioid dependence, and another product, CAM2038, is in the NDA refilling process for opioid dependence and in Phase 3 for pain management. The company aims to transform the management of opioid use disorder by eliminating stigma and improving access to treatment.
What is Braeburn's revenue?
StartupHub estimates Braeburn's annual revenue at $59.7M (range $32.8M to $137.6M, 65% confidence), based on comparable companies in the sector.
What is Braeburn's valuation?
StartupHub estimates Braeburn's effective valuation at $478.8M (range $332.5M to $798.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Braeburn raised?
Braeburn has raised a total of $133M in funding. The most recent round on record is Conventional Debt.
Where is Braeburn headquartered?
Braeburn is headquartered in Plymouth Meeting, PA, United States.
When was Braeburn founded?
Braeburn was founded in 2012.
What industry does Braeburn operate in?
Braeburn operates in Biotech, HealthTech, Drug Discovery, Biotechnology, Life Sciences, Pharmaceuticals.
How many employees does Braeburn have?
Braeburn has approximately 276 people on record.
No comments yet. Be the first to share your take.